[Long-term results of therapy for idiopathic hypothyrosis depending on the immune status]. / Otdalënnye rezul'taty terapii idiopaticheskogo gipotireoza v zavisimosti ot immunnogo statusa.

Impaired immunity in patients with idiopathic hypothyrosis affects negatively the disease course. Such patients developed exacerbations more frequently than patients with normal immune characteristics.

[The use of immunoregulator preparations in the combined treatment of idiopathic hypothyroidism]. / Primenenie immunoreguliruiushchikh preparatov v kompleksnom lechenii idiopaticheskogo gipotireoza.

A comparative analysis of idiopathic hypothyroidism (IHT) outcomes in different therapeutic regimens which incorporated or did not incorporate splenin and sodium nucleinate showed more frequent disease exacerbations in patients who received no immunoactive drugs. Combined therapy reduced the number of patients with decompensation 3.7-fold. Stable IHT compensation was achieved in those patients who had received adjuvant splenin in 80.8% of cases, sodium nucleinate in 86.2% against a 40.9% response rate under conventional replacement therapy with thyreoidin.

[Long-term results of therapy of primary hypothyroidism in relation to immune status]. / Otdalennye rezultaty terapii pervichnogo gipotireoza v zavisimosti ot immunnogo statusa.

Disorders in the immune status of patients with hypothyroidism (idiopathic and postoperative) produce a negative effect on a course of disease. Periods of decompensation (exacerbation) develop in such patients more frequently than in patients suffering from hypothyroidism with the normally or moderately changed immune status.

[Immunologic disorders in patients with primary hypothyroidism]. / Immunnye narusheniia u bol'nykh pervichnym gipotireozom.

Most patients with primary hypothyroidism showed changes in the immune status manifested in a reduction of the number and functional activity of T-lymphocytes, increased sensibilization of lymphoid cells to thyreoglobulin, content of B-lymphocytes, serum immunoglobulins of M, G classes, antithyreoglobin antibody titer and circulating immune complexes. The frequency and grade of immune disorders are directly related to the severity of the disease. The most pronounced changes were revealed in spontaneous hypothyroidism.

[Immunoactive drugs in the combined modality therapy of patients with hypothyroidism]. / Immunoaktivnye preparaty v kompleksnom lechenii bol'nykh gipotireozom.

Comparative studies into the clinico-immunologic status of patient with primary hypothyrosis have shown that the multimodality treatment including differentiated administration of immunoactive agents (glucocorticoids, splenin) promoted more well-defined normalization of cellular, humoral immunity and nonspecific defence as well as reduction or disappearance of the clinical disease manifestations as compared to patients who did not receive those drugs as part of the multimodality therapy. The use of glucocorticoids and splenin may be recommended as part of the multimodality treatment of patients suffering from primary hypothyrosis marked by pronounced disorders in the immune system.

[Changes in the immune status in primary hypothyroidism]. / Izmeneniia v immunnom statuse pri pervichnom gipotireoze.

A majority of patients with primary hypothyroidism demonstrated shifts in the immune status manifested in a decrease in the number and function of T-lymphocytes, an increase in the sensitization of lymphoid cells to thyroglobulin, the level of B-lymphocytes, serum immunoglobulins, the titer of antihyroglobulin antibodies and circulating immune complexes. The frequency and expression of immune disorders were in direct relation to the severity of disease. The most noticeable changes were detected in spontaneous-hypothyroidism. A differentiated use of immunoreactive drugs (glucocorticoids, splenin) in patients with spontaneous hypothyroidism taking into account the severity of disease and immunological indices, enhanced the effectiveness of replacement therapy, reduced the time of achieving replacement therapy, reduced the time of achieving clinical remission and contributed to the normalization of biochemical and immunological indices.